Javidi Hedayat, Ah-Moye Sarah, Hennings Charles, Mehta Hemal, Mahmood Sajjad
Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Royal Free London NHS Foundation Trust, London, UK.
Ophthalmol Ther. 2021 Jun;10(2):359-365. doi: 10.1007/s40123-021-00340-7. Epub 2021 Mar 20.
To report findings of maculopathy after treatment with sertraline in three patients.
This case series includes three patients who presented with reduced visual acuity after treatment with sertraline for various psychiatric indications. All patients had been treated with sertraline for varying periods of time between 4 weeks and 5 years.
Data were collected from three patients (age range, 27-68 years). All three patients were white females, with both eyes being affected in all cases. The range of presenting visual acuities was between 20/30 and 20/100 after presentation with central visual disturbance. All patients underwent comprehensive ocular examination and imaging with the main ocular findings being outer retinal layer and retinal pigment epithelial disruption. The follow-up period was between 1 and 9 months with final visual acuities between 20/25 and 20/100. Patients showed objective clinical evidence of phenotypically similar maculopathy supported by appropriate imaging CONCLUSION: In this cohort, we report the possible association of sertraline use and associated maculopathy in three patients. This is potentially significant, given the large numbers of patients treated with sertraline currently; however, further evidence is required to both quantify how common this association is and establish a possible causative mechanism.
报告3例舍曲林治疗后出现黄斑病变的病例。
该病例系列包括3例因各种精神疾病使用舍曲林治疗后出现视力下降的患者。所有患者使用舍曲林治疗的时间在4周至5年不等。
收集了3例患者（年龄范围27 - 68岁）的数据。所有3例患者均为白人女性，均双眼受累。出现中心视力障碍后，就诊时视力范围在20/30至20/100之间。所有患者均接受了全面的眼部检查和影像学检查，主要眼部表现为视网膜外层和视网膜色素上皮破坏。随访期为1至9个月，最终视力在20/25至20/100之间。患者表现出客观临床证据，经适当影像学检查支持为表型相似的黄斑病变。结论：在该队列中，我们报告了3例舍曲林使用与相关黄斑病变之间可能的关联。鉴于目前使用舍曲林治疗的患者数量众多，这可能具有重要意义；然而，需要进一步的证据来量化这种关联的普遍程度，并确定可能的致病机制。
